RNV Technology

Our Breakthrough RNV Technology

We believe that the most commercially-advanced cancer immunotherapeutic drugs or drug candidates have unwanted off-target side effects that activate the immune system against the cancer as well as against healthy tissue (autoimmunity). Tocagen is developing novel retroviral non-replicating vectors (“RNVs”) designed to activate the immune system selectively against the tumor without causing clinically meaningful autoimmunity. Using an earlier version of this RNV approach, Tocagen scientists and collaborators previously reported anticancer activity and prolonged survival in humans with stage 4 metastatic melanoma without serious systemic side effects (Nemunaitis et al. Hum Gene Ther, 10, 1999: 1289-1298, Nemunaitis et al. Cancer Gene Ther, 7(10), 2000: 1297–1298).

Brain Cancer (High Grade Glioma)

Product Candidates
Toca 511 & Toca FC